A Phase 1 interventional study of Tirabrutinib and Placebo in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 7th largest by enrollment, is one of 6 that started in 2016, is one of 6 in phase 1, and was the 2nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 49 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Gilead Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will consist of two parts: Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirabrutinib in healthy participants. Part B will evaluate the safety, tolerability, and the effect of tirabrutinib on disease-specific clinical markers and outcomes in participants with rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A
Part B
Exclusion Criteria
Part A
Part B
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
Drug: Tirabrutinib
Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
Drug: Placebo
Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
Drug: Tirabrutinib
Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
Drug: Placebo
Tirabrutinib 20 mg capsules orally QD for 4 weeks.
Drug: Tirabrutinib
Placebo to match tirabrutinib capsules orally QD for 4 weeks.
Drug: Placebo
Capsules administered orally.
Also known as: GS-4059
Capsules administered orally.
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days
Part A: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.
Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days
Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days
Part A: Cmax: Maximum Observed Plasma Concentration of Tirabrutinib
Cmax is maximum observed concentration of drug in plasma.
Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Part A: Clast: Last Observed Quantifiable Plasma Concentration of Tirabrutinib
Clast is the last observed concentration of drug in plasma.
Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Part A: Tmax: Time (Observed Time Point) of Cmax of Tirabrutinib
Tmax is the time observed for the Cmax of tirabrutinib.
Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Part A: Tlast: Time (Observed Time Point) of Clast of Tirabrutinib
Tlast is the time observed for the Clast of tirabrutinib.
Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib
AUC is concentration of drug over time (area under the plasma concentration versus time curve).
Time frame: Cohorts 1 and 2, Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose relative to the morning dose
Part A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of Tirabrutinib
AUC is concentration of drug over time (area under the plasma concentration versus time curve).
Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Part B: Percentage of Participants Who Experienced TEAEs
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days
Part B: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per CTCAE, version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.
Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days
Part B: Percentage of Participants With 12-Lead ECG Abnormalities
Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days
Part A: Change From Baseline in Percent Inhibition of CD63 Basophils at Days 1, 3, 5 and 7
The effect of tirabrutinib on biomarkers was assessed through the CD63 basophil activation test (BAT) FlowCast assay, which was used to measure the percentage of CD63+ basophils and percentage inhibition of CD63 induction relative to baseline. CD63+ % inhibition was calculated as 100 - CD63+ % baseline. Baseline defined as day 1 predose.
Time frame: Days 1 and 7: Predose and 2, 6, 12, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose
Part A: Change From Baseline in Percent Bruton's Tyrosine Kinase (BTK) Occupancy at Days 1, 3, 5 and 7
BTK occupancy was assessed with the BTK occupancy assay, which was used to measure undetectable free BTK, normalized free BTK, normalized free BTK adjusted to baseline, and percentage BTK occupancy adjusted to baseline. % BTK occupancy adjusted was calculated as 100 \* (1 - normalized free BTK adjusted to baseline). Normalized free BTK was calculated as Free BTK / Total BTK. Baseline defined as day 1 predose.
Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose; Day 7: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, 120 hours postdose
Part B: Change From Baseline in Disease Activity Score for 28 Joint Counts (DAS28) Using C-Reactive Protein (CRP) at Weeks 2, 4 and Posttreatment Week 4
DAS28 score was used to measure the participant's disease activity or assessments of rheumatoid arthritis (RA) calculated using the tender joint counts (TJC) (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (PtGA) (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Individual American College of Rheumatology (ACR) Component: Tender Joint Count (TJC) Based on 68 Joints (TJC68) at Weeks 2, 4 and Posttreatment Week 4
ACR TJC was an assessment of 68 joints. At each study visit, a joint evaluator assessed whether a particular joint was "tender" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all tender joints. The range for TJC68 was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Individual ACR Component: Swollen Joint Count (SJC) Based on 66 Joints (SJC66) at Weeks 2, 4 and Posttreatment Week 4
ACR SJC was an assessment of 66 joints. At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all swollen joints. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week
Part B: Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4 and Posttreatment Week 4
SDAI is a composite measure that sums the TJC based on 28 joints (TJC28), SJC based on 28 joints (SJC28), PtGA, Physician's Global Assessment of Disease Activity (PhGA), and the CRP (in mg/dL). PtGA and PhGA assessed using Visual Analogue Scale (VAS) on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4 and Posttreatment Week 4
CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PtGA) at Weeks 2, 4 and Posttreatment Week 4
PtGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to provide the patient's overall assessment of how the arthritis is doing. A mark was placed on the horizontal line to assess the current arthritis disease activity. The lowest mark indicated 'no arthritis activity', and the highest mark indicated 'extremely active arthritis'. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGA) at Weeks 2, 4 and Posttreatment Week 4
PhGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to measure the physician's assessment of the patient's current disease activity. A mark was placed on the horizontal line to assess the disease activity (independent of the participant's self-assessment). The lowest mark indicated 'no disease activity', and the highest mark indicated 'maximum disease activity'. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Pain at Weeks 2, 4 and Posttreatment Week 4
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A horizontal visual analog scale was used to assess the patient's current level of pain. A mark was placed on the horizontal line to assess the severity of pain. The lowest mark indicated 'no pain', and the highest mark indicated 'unbearable pain'. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Change From Baseline in the Health Assessment Questionnaire Disability Subscales (HAQ-DI) Score at Weeks 2, 4 and Posttreatment Week 4
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually administered by the participant. Responses in each functional category were collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Weeks 2, 4 and Posttreatment Week 4
ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity); patient's pain assessment using VAS on a scale of 0-100 (0 indicating no pain and 100 indicating unbearable pain); HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity CRP (hsCRP).
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) Response at Weeks 2, 4 and Posttreatment Week 4
ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; patient's pain assessment using VAS on a scale of 0-100 \[0 indicating no pain and 100 indicating unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Hybrid ACR Improvement Response at Weeks 2, 4 and Posttreatment Week 4
Hybrid ACR evaluates the improvement in active RA by combining elements of the ACR20, ACR50, and ACR70 with a continuous score of the mean change in core set measures. The percentage improvement from baseline was computed in each of the components of the ACR. The average percent improvement was calculated and used with the participant's ACR20, ACR50, and ACR70 status to compute the hybrid ACR response, with a positive change indicating improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Remission as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4
Clinical remission is defined as DAS28-CRP \< 2.6. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4
Low disease activity is defined as DAS28-CRP ≤ 3.2. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Remission as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4
Clinical remission is defined as CDAI ≤ 2.8. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4
Low disease activity is defined as CDAI ≤ 10. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Remission as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4
Clinical remission is defined as SDAI ≤ 3.3. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4
Low disease activity is defined as SDAI ≤ 11. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
Time frame: Weeks 2, 4 and Posttreatment Week 4
Participants were enrolled at 11 study sites in the United States. The first participant was screened on 26 January 2016. The last study visit occurred on 01 September 2016.
| Milestone | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|---|---|---|---|
| Started | 8 | 2 | 8 | 2 | 17 | 5 |
| Completed | 8 | 2 | 8 | 2 | 16 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized but never treated | 0 | 0 | 0 | 0 | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo |
|---|---|---|---|---|
| Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | 25.0 | 50.0 | 37.5 | 0 |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.
| percentage of participants | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo |
|---|---|---|---|---|
| Hemoglobin Decreased | 25.0 | 0 | 37.5 | 50.0 |
| Neutrophils Decreased | 0 | 0 | 0 | 0 |
| White Blood Cells Decreased | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase (ALT) Increased | 25.0 | 0 | 25.0 | 0 |
| Aspartate Aminotransferase (AST) Increased | 12.5 | 0 | 25.0 | 0 |
| Alkaline Phosphatase Increased | 0 | 0 | 12.5 | 0 |
| Amylase | 12.5 | 0 | 0 | 0 |
| Calcium Increased | 12.5 | 0 | 0 | 0 |
| Fasting Glucose Increased | 12.5 | 0 | 0 | 0 |
| Gamma-glutamyl Transferase (GGT) Increased | 25.0 | 0 | 0 | 0 |
| Glucose Increased | 12.5 | 0 | 0 | 0 |
| Phosphorus Decreased | 12.5 | 0 | 0 | 0 |
| Sodium Decreased | 0 | 50.0 | 0 | 0 |
| Total Cholesterol Increased | 25.0 | 0 | 12.5 | 100.0 |
| Triglycerides Increased | 25.0 | 0 | 37.5 | 50.0 |
| Magnesium Increased | 0 | 0 | 0 | 0 |
| Potassium Decreased | 0 | 0 | 0 | 0 |
| percentage of participants | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo |
|---|---|---|---|---|
| Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 |
Cmax is maximum observed concentration of drug in plasma.
| nanogram per milliliter (ng/mL) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Day 1 | 33.8 ± 7.94 | 16.2 ± 4.66 |
| Day 7 | 56.4 ± 11.19 | 32.3 ± 8.59 |
Clast is the last observed concentration of drug in plasma.
| ng/mL | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Day 1 | 2.58 ± 1.366 | 5.22 ± 1.729 |
| Day 7 | 1.50 ± 0.551 | 2.03 ± 0.756 |
Tmax is the time observed for the Cmax of tirabrutinib.
| hours | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Day 1 | 2.00 (1.50 to 4.00) | 3.00 (1.50 to 4.00) |
| Day 7 | 2.00 (1.50 to 3.00) | 2.00 (1.50 to 4.00) |
Tlast is the time observed for the Clast of tirabrutinib.
| hours | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Day 1 | 23.92 (12.00 to 23.92) | 11.92 (11.92 to 12.00) |
| Day 7 | 30.00 (24.00 to 48.00) | 24.00 (18.00 to 36.00) |
AUC is concentration of drug over time (area under the plasma concentration versus time curve).
| hours*nanogram per milliliter (h*ng/mL) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib | 360.5 ± 97.49 | 195.2 ± 44.43 |
AUC is concentration of drug over time (area under the plasma concentration versus time curve).
| h*ng/mL | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID |
|---|---|---|
| Day 1 | 228.3 ± 89.96 | 107.1 ± 27.54 |
| Day 7 | 377.8 ± 119.80 | 245.5 ± 65.02 |
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Part B: Percentage of Participants Who Experienced TEAEs | 37.5 | 40.0 |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per CTCAE, version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Hemoglobin Decreased | 6.3 | 0 |
| Neutrophils Decreased | 6.3 | 0 |
| White Blood Cells Decreased | 6.3 | 0 |
| Alanine Aminotransferase (ALT) Increased | 12.5 | 20.0 |
| Fasting Glucose Increased | 12.5 | 20.0 |
| Glucose Increased | 12.5 | 20.0 |
| Magnesium Increased | 18.8 | 0 |
| Potassium Decreased | 12.5 | 0 |
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Part B: Percentage of Participants With 12-Lead ECG Abnormalities | 0 | 0 |
The effect of tirabrutinib on biomarkers was assessed through the CD63 basophil activation test (BAT) FlowCast assay, which was used to measure the percentage of CD63+ basophils and percentage inhibition of CD63 induction relative to baseline. CD63+ % inhibition was calculated as 100 - CD63+ % baseline. Baseline defined as day 1 predose.
| percentage of Inhibition | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo |
|---|---|---|---|---|
| Day 1, Predose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Day 1, 2 Hours Postdose | 17.189 ± 6.8306 | 0.272 ± 2.3326 | 19.557 ± 11.0479 | 3.568 ± 1.4734 |
| Day 1, 6 Hours Postdose | 34.966 ± 15.6436 | 8.779 ± 9.9101 | 27.506 ± 16.0744 | 1.782 ± 6.3117 |
| Day 1, 12 Hours Postdose | — | — | 35.008 ± 24.1663 | -2.688 ± 16.7688 |
| Day 1, 24 Hours Postdose | 33.305 ± 14.9248 | 5.604 ± 1.2275 | — | — |
| Day 3, Predose | 47.416 ± 17.0470 | 0.917 ± 11.4281 | 83.832 ± 10.1042 | -11.354 ± 16.5029 |
| Day 3, 2 Hours Postdose | 73.972 ± 15.1658 | -0.842 ± 4.6395 | 90.187 ± 5.6699 | -13.641 ± 13.0667 |
| Day 5, Predose | 55.680 ± 21.5018 | 2.779 ± 3.7023 | 83.380 ± 10.3976 | -2.271 ± 0.2060 |
| Day 5, 2 Hours Postdose | 80.271 ± 16.8806 | -0.043 ± 2.3069 | 91.159 ± 7.4740 | -15.923 ± 11.5733 |
| Day 7, Predose | 56.986 ± 20.3972 | 5.234 ± 0.8757 | 80.024 ± 11.0371 | 6.271 ± 7.9790 |
| Day 7, 2 Hours Postdose | 79.910 ± 15.3155 | -2.831 ± 0.7358 | 88.032 ± 7.8750 | -0.978 ± 9.9380 |
| Day 7, 6 Hours Postdose | 88.102 ± 11.6072 | -1.320 ± 8.1776 | 89.681 ± 7.0909 | -2.645 ± 6.3382 |
| Day 7, 12 Hours Postdose | — | — | 80.640 ± 10.0574 | -10.062 ± 13.2554 |
| Day 7, 24 Hours Postdose | 52.017 ± 17.5829 | -0.046 ± 0.6432 | — | — |
BTK occupancy was assessed with the BTK occupancy assay, which was used to measure undetectable free BTK, normalized free BTK, normalized free BTK adjusted to baseline, and percentage BTK occupancy adjusted to baseline. % BTK occupancy adjusted was calculated as 100 \* (1 - normalized free BTK adjusted to baseline). Normalized free BTK was calculated as Free BTK / Total BTK. Baseline defined as day 1 predose.
| percentage of BTK occupancy | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo |
|---|---|---|
| Day 1, Predose | 0 ± 0 | 0 ± 0 |
| Day 1, 0.5 Hour Postdose | -2.765 ± 14.6036 | -4.686 ± 1.8358 |
| Day 1, 1 Hour Postdose | 11.635 ± 17.8025 | -11.927 ± 8.4893 |
| Day 1, 2 Hours Postdose | 55.250 ± 10.0230 | -8.959 ± 16.7122 |
| Day 1, 3 Hours Postdose | 62.719 ± 7.7060 | -9.810 ± 18.8212 |
| Day 1, 4 Hours Postdose | 66.790 ± 7.9494 | -16.597 ± 25.0492 |
| Day 1, 6 Hours Postdose | 71.936 ± 8.3606 | -6.014 ± 19.5348 |
| Day 1, 8 Hours Postdose | 75.350 ± 11.5216 | -16.584 ± 17.8202 |
| Day 1, 12 Hours Postdose | 77.411 ± 8.6928 | 6.170 ± 12.7312 |
| Day 1, 18 Hours Postdose | 81.187 ± 8.8687 | -2.261 ± 27.3338 |
| Day 1, 24 Hours Postdose | 72.691 ± 10.8289 | -28.029 ± 10.1821 |
| Day 3, Predose | 84.010 ± 8.4919 | -19.564 ± 20.3282 |
| Day 3, 2 Hours Postdose | 90.606 ± 6.1066 | -35.206 ± 25.2258 |
| Day 5, Predose | 70.841 ± 43.0596 | 25.095 ± 99.0827 |
| Day 5, 2 Hours Postdose | 93.128 ± 4.0582 | -25.646 ± 17.6912 |
| Day 7, Predose | 86.936 ± 6.4745 | -22.662 ± 23.6252 |
| Day 7, 0.5 Hours Postdose | 87.013 ± 5.2426 | -23.284 ± 9.9539 |
| Day 7, 1 Hour Postdose | 86.274 ± 6.0720 | -12.230 ± 6.6727 |
| Day 7, 2 Hours Postdose | 92.651 ± 3.4603 | -34.573 ± 17.9620 |
| Day 7, 3 Hours Postdose | 92.983 ± 2.1906 | -32.920 ± 20.1029 |
| Day 7, 4 Hours Postdose | 90.070 ± 7.4086 | -37.253 ± 16.2208 |
| Day 7, 6 Hours Postdose | 91.591 ± 7.7733 | -39.632 ± 13.1749 |
| Day 7, 8 Hours Postdose | 92.789 ± 3.2221 | -31.144 ± 20.1974 |
| Day 7, 12 Hours Postdose | 91.251 ± 6.0300 | -33.947 ± 16.3475 |
| Day 7, 18 Hours Postdose | 85.209 ± 5.0694 | -34.408 ± 12.5471 |
| Day 7, 24 Hours Postdose | 86.256 ± 6.5648 | -42.577 ± 17.2138 |
| Day 7, 36 Hours Postdose | 71.963 ± 10.5550 | -43.574 ± 8.4952 |
| Day 7, 48 Hours Postdose | 64.763 ± 14.3072 | -46.249 ± 24.2785 |
| Day 7, 60 Hours Postdose | 57.431 ± 9.0638 | -15.465 ± 9.4556 |
| Day 7, 72 Hours Postdose | 46.218 ± 14.3155 | -49.093 ± 21.4447 |
| Day 7, 96 Hours Postdose | 24.922 ± 6.8700 | -41.721 ± 32.0255 |
| Day 7, 120 Hours Postdose | 15.285 ± 9.4140 | -48.863 ± 20.7533 |
DAS28 score was used to measure the participant's disease activity or assessments of rheumatoid arthritis (RA) calculated using the tender joint counts (TJC) (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (PtGA) (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 4.54 ± 1.728 | 5.12 ± 1.576 |
| Change from Baseline at Week 2 | -0.35 ± 0.821 | -0.28 ± 0.977 |
| Change from Baseline at Week 4 | -0.45 ± 1.097 | -0.11 ± 0.612 |
| Change from Baseline at Posttreatment Week 4 | -0.41 ± 1.208 | -0.05 ± 0.782 |
ACR TJC was an assessment of 68 joints. At each study visit, a joint evaluator assessed whether a particular joint was "tender" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all tender joints. The range for TJC68 was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.
| tender joint count | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 18.20 ± 14.454 | 21.70 ± 12.656 |
| Change from Baselline at Week 2 | -2.57 ± 6.666 | -1.17 ± 7.980 |
| Change from Baselline at Week 4 | -6.69 ± 8.432 | 0.01 ± 0.829 |
| Change from Baselline at Posttreatment Week 4 | -3.13 ± 9.968 | 1.11 ± 12.638 |
ACR SJC was an assessment of 66 joints. At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all swollen joints. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.
| swollen joint count | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 12.70 ± 10.944 | 12.04 ± 12.488 |
| Change from Baseline at Week 2 | -4.13 ± 6.446 | -2.58 ± 9.910 |
| Change from Baseline at Week 4 | -4.82 ± 7.586 | -2.23 ± 6.048 |
| Change from Baseline at Posttreatment Week 4 | -3.07 ± 5.272 | 1.53 ± 3.035 |
SDAI is a composite measure that sums the TJC based on 28 joints (TJC28), SJC based on 28 joints (SJC28), PtGA, Physician's Global Assessment of Disease Activity (PhGA), and the CRP (in mg/dL). PtGA and PhGA assessed using Visual Analogue Scale (VAS) on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 30.19 ± 20.283 | 33.20 ± 19.061 |
| Change from Baseline at Week 2 | -4.49 ± 11.786 | -5.20 ± 14.035 |
| Change from Baseline at Week 4 | -6.84 ± 14.016 | -1.69 ± 5.439 |
| Change from Baseline at Posttreatment Week 4 | -4.82 ± 14.349 | -1.16 ± 12.293 |
CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 29.63 ± 19.994 | 31.96 ± 18.622 |
| Change from Baseline at Week 2 | -4.44 ± 11.748 | -5.32 ± 13.264 |
| Change from Baseline at Week 4 | -6.80 ± 13.925 | -2.02 ± 5.206 |
| Change from Baseline at Posttreatment Week 4 | -4.73 ± 14.180 | -1.74 ± 11.562 |
PtGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to provide the patient's overall assessment of how the arthritis is doing. A mark was placed on the horizontal line to assess the current arthritis disease activity. The lowest mark indicated 'no arthritis activity', and the highest mark indicated 'extremely active arthritis'. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 42 ± 27.4 | 63 ± 30.5 |
| Change from Baseline at Week 2 | -10 ± 20.7 | -6 ± 17.6 |
| Change from Baseline at Week 4 | -10 ± 22.1 | -10 ± 16.7 |
| Change from Baseline at Posttreatment Week 4 | -4 ± 22.2 | -9 ± 17.8 |
PhGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to measure the physician's assessment of the patient's current disease activity. A mark was placed on the horizontal line to assess the disease activity (independent of the participant's self-assessment). The lowest mark indicated 'no disease activity', and the highest mark indicated 'maximum disease activity'. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 39 ± 27.4 | 49 ± 15.5 |
| Change from Baseline at Week 2 | -3 ± 23.5 | -16 ± 13.4 |
| Change from Baseline at Week 4 | -8 ± 20.3 | 5 ± 14.9 |
| Change from Baseline at Posttreatment Week 4 | -4 ± 22.7 | -3 ± 17.7 |
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A horizontal visual analog scale was used to assess the patient's current level of pain. A mark was placed on the horizontal line to assess the severity of pain. The lowest mark indicated 'no pain', and the highest mark indicated 'unbearable pain'. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 39 ± 28.6 | 59 ± 28.9 |
| Change from Baseline at Week 2 | -5 ± 26.2 | -6 ± 15.7 |
| Change from Baseline at Week 4 | -9 ± 24.6 | -13 ± 16.2 |
| Change from Baseline at Posttreatment Week 4 | -2 ± 22.9 | -11 ± 24.9 |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually administered by the participant. Responses in each functional category were collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. A negative change from baseline indicates improvement.
| score on a scale | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Baseline | 1.063 ± 0.7130 | 1.650 ± 0.7776 |
| Change from Baseline at Week 2 | -0.203 ± 0.5242 | -0.150 ± 0.2054 |
| Change from Baseline at Week 4 | -0.234 ± 0.4492 | -0.100 ± 0.3687 |
| Change from Baseline at Posttreatment Week 4 | -0.156 ± 0.3550 | 0.094 ± 0.1197 |
ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity); patient's pain assessment using VAS on a scale of 0-100 (0 indicating no pain and 100 indicating unbearable pain); HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity CRP (hsCRP).
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2 | 6.3 | 20.0 |
| Week 4 | 18.8 | 0 |
| Posttreatment Week 4 | 12.5 | 0 |
ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; patient's pain assessment using VAS on a scale of 0-100 \[0 indicating no pain and 100 indicating unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| At Week 2 | 0 | 0 |
| At Week 4 | 6.3 | 0 |
| At Posttreatment Week 4 | 0 | 0 |
Hybrid ACR evaluates the improvement in active RA by combining elements of the ACR20, ACR50, and ACR70 with a continuous score of the mean change in core set measures. The percentage improvement from baseline was computed in each of the components of the ACR. The average percent improvement was calculated and used with the participant's ACR20, ACR50, and ACR70 status to compute the hybrid ACR response, with a positive change indicating improvement.
| percent improvement | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| At Week 2 | 1.51 ± 30.687 | 4.41 ± 25.410 |
| At Week 4 | 3.29 ± 36.098 | -4.06 ± 14.459 |
| At Posttreatment Week 4 | 0.44 ± 34.589 | -7.65 ± 20.606 |
Clinical remission is defined as DAS28-CRP \< 2.6. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Remission based on DAS28-CRP (< 2.6) | 12.5 | 0 |
| Week 4: Remission based on DAS28-CRP (< 2.6) | 12.5 | 0 |
| Post Week 4: Remission based on DAS28-CRP (< 2.6) | 25.0 | 0 |
Low disease activity is defined as DAS28-CRP ≤ 3.2. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Low Disease Activity on DAS28-CRP (<= 3.2) | 18.8 | 20.0 |
| Week 4: Low Disease Activity on DAS28-CRP (<= 3.2) | 12.5 | 20.0 |
| Post Week4: Low Disease Activity DAS28-CRP (<=3.2) | 37.5 | 0 |
Clinical remission is defined as CDAI ≤ 2.8. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Remission based on CDAI (<= 2.8) | 12.5 | 0 |
| Week 4: Remission based on CDAI (<= 2.8) | 6.3 | 0 |
| Post Week 4: Remission based on CDAI (<= 2.8) | 6.3 | 0 |
Low disease activity is defined as CDAI ≤ 10. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Low Disease Activity based on CDAI (<= 10) | 18.8 | 20.0 |
| Week 4: Low Disease Activity based on CDAI (<= 10) | 18.8 | 20.0 |
| Post Week 4: Low Disease Activity on CDAI (<= 10) | 31.3 | 20.0 |
Clinical remission is defined as SDAI ≤ 3.3. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Remission based on SDAI (<= 3.3) | 12.5 | 0 |
| Week 4: Remission based on SDAI (<= 3.3) | 6.3 | 0 |
| Post Week 4: Remission based on SDAI (<= 3.3) | 6.3 | 0 |
Low disease activity is defined as SDAI ≤ 11. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Part B: Tirabrutinib 20 mg QD | Part B: Placebo |
|---|---|---|
| Week 2: Low Disease Activity based on SDAI (<= 11) | 25.0 | 20.0 |
| Week 4: Low Disease Activity based on SDAI (<= 11) | 18.8 | 20.0 |
| Post Week 4: Low Disease Activity on SDAI (<= 11) | 37.5 | 20.0 |
Collected over Adverse Events: Part A: First dose date up to last dose (maximum: 7 days) plus 30 days; Part B: First dose date up to last dose (maximum: 29 days) plus 30 days; All-Cause Mortality: First dose date up to approximately 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1, Part A: Tirabrutinib 20 mg QD | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Cohort 2, Part A: Tirabrutinib 10 mg BID | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Part B: Tirabrutinib 20 mg QD | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| All Placebo | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Event | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 2, Part A: Tirabrutinib 10 mg BID | Part B: Tirabrutinib 20 mg QD | All Placebo |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/8 | 2/8 | 0/16 | 0/9 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/8 | 0/8 | 0/16 | 1/9 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 | 0/16 | 0/9 |
| Muscle strainInjury, poisoning and procedural complications | 0/8 | 1/8 | 0/16 | 0/9 |
| HeadacheNervous system disorders | 0/8 | 1/8 | 1/16 | 0/9 |
| Abdominal tendernessGastrointestinal disorders | 0/8 | 0/8 | 0/16 | 1/9 |
| Urinary tract infectionInfections and infestations | 0/8 | 0/8 | 0/16 | 1/9 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 1/16 | 1/9 |
| Thyroid massEndocrine disorders | 0/8 | 0/8 | 1/16 | 0/9 |
| ExtravasationGeneral disorders | 0/8 | 0/8 | 1/16 | 0/9 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo | Part B: Tirabrutinib 20 mg QD | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 38 (30 to 44) | 37 (29 to 44) | 34 (22 to 45) | 38 (33 to 43) | 55 (38 to 64) | 52 (35 to 64) | 45.5 (22 to 64) |
| Sex: Female, Male(Participants) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo | Part B: Tirabrutinib 20 mg QD | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 2 | 0 | 13 | 4 | 24 |
| Male | 4 | 1 | 6 | 2 | 3 | 1 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo | Part B: Tirabrutinib 20 mg QD | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 2 | 8 | 2 | 2 | 2 | 24 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 14 | 3 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1, Part A: Tirabrutinib 20 mg QD | Cohort 1, Part A: Placebo | Cohort 2, Part A: Tirabrutinib 10 mg BID | Cohort 2, Part A: Placebo | Part B: Tirabrutinib 20 mg QD | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Race — Black | 4 | 0 | 0 | 1 | 0 | 0 | 5 |
| Race — White | 4 | 2 | 8 | 1 | 16 | 5 | 36 |
Ran from Jan 2016 to primary completion in Sep 2016, 7 months.
Results were first posted in Sep 2020, 4 years after primary completion.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 7 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirabrutinib